Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003334 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
A Phase 2 study of Ovarian Cancer and Endometrial Cancer, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Study locations
NCT00003334: Completed Phase 2 study of Ovarian Cancer and Endometrial Cancer, sponsored by NYU Langone Health.
NCT00003334 is a Phase 2 study of Ovarian Cancer and Endometrial Cancer that has completed, run by NYU Langone Health. The trial reports 5 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003334, a Phase 2 study of Ovarian Cancer and Endometrial Cancer, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining doxorubicin and paclitaxel in treating patients who have recurrent or refractory endometrial cancer, fallopian tube cancer, or sarcoma of the female reproductive tract.
Conditions Studied
Interventions
- DRUG paclitaxel
- DRUG pegylated liposomal doxorubicin hydrochloride
Study Locations (5)
New York
- NYU School of Medicine's Kaplan Comprehensive Cancer Center - New York
- New York Presbyterian Hospital - Cornell Campus - New York
- Mount Sinai Medical Center, NY - New York
- Albert Einstein Comprehensive Cancer Center - The Bronx
- New York Medical College - Valhalla
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-03 |
| Phase | Phase 2 |
What the finished NCT00003334 record still lists
NCT00003334 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 4 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which paclitaxel is the first listed.
NCT00003334 lists 5 locations in 1 state (New York).
Frequently Asked Questions
What is clinical trial NCT00003334 about?
NCT00003334 is a clinical study titled "Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining doxorubicin and paclitaxel in treating patients who have re...
What is the current status of trial NCT00003334?
This trial is currently completed. It is a Phase 2 study. The study started on 1997-03.
What conditions does trial NCT00003334 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Sarcoma, Fallopian Tube Cancer.
What interventions are being tested in trial NCT00003334?
The interventions under investigation include: paclitaxel (DRUG), pegylated liposomal doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003334?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003334 being conducted?
This trial has 5 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia